Drug Profile
Research programme: gene therapies - Poseida Therapeutics
Alternative Names: P-HBB-101Latest Information Update: 28 Jan 2021
Price :
$50
*
At a glance
- Originator Poseida Therapeutics
- Class Gene therapies
- Mechanism of Action Gene transference
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Haematological disorders; Liver disorders
Most Recent Events
- 28 Jan 2021 No recent reports of development identified for research development in Haematological-disorders in USA
- 28 Jan 2021 No recent reports of development identified for research development in Liver-disorders in USA
- 13 Feb 2019 Poseida Therapeutics receives patent allowance for a patent protecting its piggyBac® DNA Modification System in USA